Cisplatin is widely used as part of first-line therapy for many cancer types, including bladder, ovarian, cervical, testicular, lung and breast cancer, as well as sarcomas, lymphomas and leukemias.

These ingenious compounds bring together the DNA-damaging power of cisplatin and the immune-activating strength of STING agonist MSA-2. Excitingly, these conjugates exhibit remarkable potential as ...

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the ...

Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of ...

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

The reference arm of paciltaxel and cisplatin for the Monk et al. 3 trial was selected on the basis of results from a GOG randomized phase III study, which demonstrated an improvement in objective ...

The second group received no neoadjuvant therapy prior to surgery, followed by either standard of care radiotherapy with cisplatin (100mg/m 2 IV Q3W for 3 cycles) as adjuvant therapy following ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Find all the commercial and brand names of generic drug called Cisplatin. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...

The NOTOXIS trial (ClinicalTrials.gov ID: NCT05628233) evaluates the efficacy of SENS-401 in preventing CIO in adult patients with neoplastic disease, four weeks after completion of cisplatin ...